Dr Lal PathLabs

November 04, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Symbol: LALPATHLAB

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 539524

**Sub: Outcome of Board Meeting held on November 04, 2026**
**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")**

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. November 04, 2026, inter-alia considered, noted and approved the following(s):

**Financial Results**

1. Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30, 2026.

   A signed copy of the above Financial Results (Standalone & Consolidated) along with Limited Review Report issued by Statutory Auditors thereon under Regulation 33 of the Listing Regulations is attached herewith as **"Annexure- A".**

**Interim Dividend**

2. Declaration of 2nd Interim Dividend of INR 5/- per equity share (@ 50% on a face value of INR 10/- each) for the financial year 2026-27. The record date for the purpose of payment of 2nd Interim Dividend shall be November 11, 2026.

   The 2nd Interim Dividend will be paid within 30 days of its declaration.

**Appointment of Director**

3. Based on the recommendation of Nomination and Remuneration Committee, the Appointment of Ms. Vasuta Agarwal (DIN: 07480674) as an Additional Director designated as a Non-Executive Independent Director on the Board of the Company, for a term of three (3) consecutive years commencing from November 04, 2026, subject to approval of Members of the Company through postal ballot.

   Please also take note that Ms. Vasuta Agarwal is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority.

   The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time are enclosed herewith as **"Annexure – B"**.

**Further investment in Subsidiary Company**

4. Further investment(s) of an amount upto INR 49.5 Crores in Dr. Lal PathLabs FZCO, ("LPL Dubai"), a Wholly Owned Subsidiary of the Company, in one or more tranches, for meeting its business and operational requirements, including making further investment in its subsidiary, Sunshine Healthcare Limited ("SHL"), Ghana.

   The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time is enclosed herewith as **"Annexure – C"**.

The Board Meeting commenced at 11:49 A.M. (IST) and concluded at 01:20 P.M. (IST).

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay Gujral
Digitally signed by Vinay Gujral
Date: 2026.11.04 13:23:32 +05'30'

**Vinay Gujral**
**Company Secretary & Compliance Officer**
*Encl.: As above*

**Deloitte**
**Haskins & Sells LLP**

**Chartered Accountants**
7th Floor Building 10
Tower B
DLF Cyber City Complex
DLF City Phase II
Gurugram-122 002
Haryana, India

Tel: +91 124 679 2000
Fax: +91 124 679 2012

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF**
**Dr. LAL PATHLABS LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Dr. Lal PathLabs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and six months ended September 30, 2026 ('the Statement'), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entities:

   a) Dr. Lal PathLabs Limited, the Parent company
   b) Paliwal Diagnostics Private Limited, a subsidiary company
   c) Dr. Lal PathLabs Nepal Private Limited, a subsidiary company
   d) Dr. Lal PathLabs Bangladesh Private Limited, a subsidiary company
   e) Dr. Lal Ventures Private Limited, a subsidiary company
   f) Neuome Technologies Private Limited (w.e.f August 27, 2026), an Associate Company
   g) PathLabs Unifiers Private Limited, a subsidiary company
   h) Centrapath Labs Private Limited, a step-down subsidiary company
   i) APRL PathLabs Private Limited, a step-down subsidiary company
   j) Chanre Laboratory Private Limited, a step-down subsidiary company
   k) Shahbazkers Diagnostic Centre Private Limited, a subsidiary company (w.e.f. May 01, 2026)
   l) Dr. Lal Pathlabs FZCO, a subsidiary company (w.e.f. June 12, 2026)
   m) Sunshine Health care, Ghana (w.e.f. August 04, 2026) a step-down subsidiary company
   n) Dr Lal Pathlabs Indomed LLC (w.e.f. August 19, 2026) a step-down subsidiary company

Deloitte Haskins & Sells LLP Chartered Accountants

**Deloitte**
**Haskins & Sells LLP**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The unaudited Consolidated Financial Results include the unaudited interim financial results and other unaudited financial information of six subsidiary companies which have not been reviewed by their auditors and have been approved and furnished to us by the Management, whose interim financial results reflect total assets of Rupees 1,233.81 Million as at September 30, 2026, total revenue of Rupees 133.99 Million and Rupees 210.38 Million for the quarter and six months ended September 30, 2026 respectively, total profit after tax of Rupees 24.86 Million and Rupees 33.01 Million for the quarter and six months ended September 30, 2026 respectively, and total comprehensive income of Rupees 18.32 Million and Rupees 27.57 Million for the quarter and six months ended September 30, 2026 respectively and net cash inflows of Rupees 234.78 Million for the half year ended September 30, 2026 as considered in the Statement. The Statement also includes the Group's share of net loss of Rupees 1.05 Million and Rupees 1.05 Million and total comprehensive loss of Rupees 1.05 Million and Rupees 1.05 Million for the quarter and half year ended September 30, 2026 respectively, as considered in the Statement, in respect of an associate, referred in paragraph 4 above. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate is based solely on such unaudited interim financial results and other unaudited financial information certified by the Management. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

   Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the financial results certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm Registration No.: 117366W/W-100018)




**RASHIM TANDON**
Partner
Membership No: 95540)
(UDIN: 26095540UMXYBK8286)

Place: Gurugram
Date: November 4, 2026

**Dr. Lal PathLabs Limited**

**CIN: L74899DL1995PLC065388**

**Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi**

**Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana**

**Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com**

**Statement of Consolidated Unaudited Financial Results for the quarter and six months ended 30 September, 2026**

**(INR in million except as stated)**

| | Particulars | 3 months ended 30 September, 2026 | Preceding 3 months ended 30 June, 2026 | Corresponding 3 months ended in previous year 30 September, 2025 | Year to date figures for the current period ended 30 September, 2026 | Year to date figures for the pervious period ended 30 September, 2025 | Previous year ended 31 March, 2026 |
|---|---|---|---|---|---|---|---|
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | **Income** | | | | | | |
| | (a) Revenue from operations | 8,739 | 7,977 | 7,306 | 16,716 | 14,004 | 27,629 |
| | (b) Other income | 343 | 319 | 248 | 662 | 529 | 1,013 |
| | **Total income** | **9,082** | **8,296** | **7,554** | **17,378** | **14,533** | **28,642** |
| 2 | **Expenses** | | | | | | |
| | (a) Cost of materials consumed | 1,619 | 1,517 | 1,418 | 3,136 | 2,707 | 5,346 |
| | (b) Employee benefits expense | 1,386 | 1,327 | 1,236 | 2,713 | 2,478 | 5,033 |
| | (c) Finance costs | 70 | 63 | 48 | 133 | 95 | 228 |
| | (d) Depreciation and amortisation expense | 469 | 444 | 405 | 913 | 751 | 1,618 |
| | (e) Fees to collection centers/channel partners | 1,289 | 1,158 | 1,087 | 2,447 | 2,045 | 4,024 |
| | (f) Other expenses | 1,643 | 1,500 | 1,324 | 3,143 | 2,610 | 5,401 |
| | **Total expenses** | **6,476** | **6,009** | **5,518** | **12,485** | **10,686** | **21,650** |
| 3 | Share of Profit/(Loss) of Associate (see note vii(e)) | (1) | - | - | (1) | - | - |
| 4 | **Profit before exceptional items and tax** | **2,605** | **2,287** | **2,036** | **4,892** | **3,847** | **6,992** |
| 5 | **Exceptional items**<br>Impact of Labour Codes (see note xi) | - | - | - | - | - | 301 |
| 6 | **Profit before tax** | **2,605** | **2,287** | **2,036** | **4,892** | **3,847** | **6,691** |
| 7 | **Tax expense** | | | | | | |
| | (a) Current tax | 658 | 597 | 473 | 1,255 | 923 | 1,592 |
| | (b) Deferred tax | 8 | (15) | 41 | (7) | 62 | 1 |
| | **Total tax expense** | **666** | **582** | **514** | **1,248** | **985** | **1,593** |
| 8 | **Profit for the period (A)** | **1,939** | **1,705** | **1,522** | **3,644** | **2,862** | **5,098** |
| 9 | **Other comprehensive income/(loss)** | | | | | | |
| | Items that will not be reclassified to profit or loss<br>-Remeasurement of the defined benefit obligations | (8) | 17 | 18 | 9 | 6 | 67 |
| | -Income tax in relation to the items that will not be reclassified to profit or loss | (1) | (4) | (5) | (5) | (2) | (17) |
| | Items that may be reclassified to profit or loss<br>-Exchange differences on translation of foreign operations | (6) | 1 | 2 | (5) | 2 | 2 |
| | **Total other comprehensive income/ (loss) (B)** | **(15)** | **14** | **15** | **(1)** | **6** | **52** |
| 10 | **Total comprehensive income (A+B)** | **1,924** | **1,719** | **1,537** | **3,643** | **2,868** | **5,150** |
| | **Profit for the period attributable to:** | | | | | | |
| | Owners of the Company | 1,922 | 1,695 | 1,506 | 3,617 | 2,830 | 5,048 |
| | Non-controlling interest | 17 | 10 | 16 | 27 | 32 | 50 |
| | | **1,939** | **1,705** | **1,522** | **3,644** | **2,862** | **5,098** |
| | **Other comprehensive income/(loss) for the period attributable to:** | | | | | | |
| | Owners of the Company | (15) | 14 | 15 | (1) | 6 | 52 |
| | Non-controlling interest | - | - | - | - | - | - |
| | | **(15)** | **14** | **15** | **(1)** | **6** | **52** |
| | **Total comprehensive income for the period attributable to:** | | | | | | |
| | Owners of the Company | 1,907 | 1,709 | 1,521 | 3,616 | 2,836 | 5,100 |
| | Non-controlling interest | 17 | 10 | 16 | 27 | 32 | 50 |
| | | **1,924** | **1,719** | **1,537** | **3,643** | **2,868** | **5,150** |
| 11 | Paid-up equity share capital<br>(Face Value of INR 10 per share) | 1,678 | 1,676 | 838 | 1,678 | 838 | 1,676 |
| 12 | Other equity | | | | | | 23,406 |
| 13 | Earnings per share (INR)<br>(Face value of INR 10 per share)<br>(not annualised for quarters) (see note x) | | | | | | |
| | -Basic | 11.51 | 10.15 | 9.03 | 21.65 | 16.97 | 30.24 |
| | -Diluted | 11.47 | 10.13 | 9.01 | 21.61 | 16.94 | 30.20 |

**Dr. Lal PathLabs Limited**

**Notes to the Consolidated Financials Results**

**Notes:**

i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 October, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended September 30, 2026 and they have expressed an unmodified conclusion on the aforesaid results.

ii. As at 30 September,2026, the Parent company has the following subsidiaries:

| **Subsidiaries** | **Step-down subsidiaries** | **Associate Company** |
|---|---|---|
| Paliwal Diagnostics Private Limited | Centrapath Labs Private Limited | Neuome Technologies Private Limited |
| Dr. Lal PathLabs Nepal Private Limited | APRL PathLabs Private Limited | (w.e.f 27 August, 2026) |
| Dr. Lal PathLabs Bangladesh Private Limited | Chanre Laboratory Private Limited | |
| Dr. Lal Ventures Private Limited | Sunshine Healthcare Limited | |
| PathLabs Unifiers Private Limited | (w.e.f 4 August, 2026) | |
| Dr Lal Pathlabs FZCO (w.e.f 12 June , 2026) | Dr Lal PathLabs Indomed LLC | |
| Shahbazker Diagnostics Centre Private Limited | (w.e.f 19 August, 2026) | |
| (w.e.f 1 May, 2026) | | |

iii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').

iv. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

v. During the quarter and six months ended 30 September 2026, the Parent Company has issued 211,050 and 293,800 equity shares of face value of INR 10 each respectively , to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").

vi. The Board of Directors of the Parent Company have approved second interim dividend of INR 5 per equity share (face value of INR 10 each) at their meeting held on 4 November, 2026

The Board of Directors of the Parent Company had approved an interim dividend of INR 5 per equity share (face value of INR 10 each) at their meeting held on 24 July, 2026 and this was paid on 11 August, 2026

The Board of Directors of the Company had proposed final dividend of INR 4 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2026. The same was approved by the shareholders in the Annual General Meeting held on 25 July, 2026 and this was paid on 31 July, 2026

vii. **Acquistions during the half year ended 30 September, 2026**

**a.** During the six months ended 30 September, 2026, the Parent Company has acquired 100% Stake in Shahbazkers Diagnostic Centre Private Limited ("SDCPL") on 1 May, 2026 as per the terms and conditions of the Share Purchase Agreement for a cash consideration of INR 200 million. Pursuant to completion of the aforesaid acquisition, Shahbazkers Diagnostic Centre Private Limited has now become a wholly-owned subsidiary of the Company. SDCPL is primarily engaged in providing diagnostics and healthcare services. The acquisition was accounted for as a business combination using the acquisition method of accounting, in accordance with Ind AS 103 'Business Combination'. The Purchase price has been allocated on a provisional basis to the net identifiable assets resulting in goodwill of INR 143 million.

**b.** During the six months ended 30 September 2026, A wholly owned subsidiary, Dr Lal Pathlabs FZCO has been incorporated in Dubai, United Arab Emirates. The Parent Company has subscribed to 19,135 equity shares for AED 1000 each for a total consideration of AED 19 million.

Dr Lal Pathlabs FZCO (wholly owned subsidiary) has incorporated a Company named Dr Lal PathLabs Indomed LLC in Tashkent, Uzbekistan and has subscribed to 70% of its share capital.

**c.** During the six months ended 30 September 2026, the Parent Company has made a further investment of INR 77.50 million in its wholly owned subsidiary, Dr. Lal Ventures Private Limited, through subscription of additional equity shares.

**d.** The Board of Directors of Dr Lal PathLabs FZCO (a wholly owned subsidiary) in their meeting held on 24 July 2026 has approved acquisition of equity stake of 80% stake and to purchase another 20% equity stake in tranches in Sunshine Healthcare Limited located in Ghana engaged in diagnostics business for a total consideration not exceeding GHS 57 million. The acquisition was accounted for as a business combination using the acquisition method of accounting, in accordance with Ind AS 103 'Business Combination'. The Purchase price has been allocated on a provisional basis to the net identifiable assets resulting in goodwill of INR 239 million.

**e.** The Board of Directors of Dr. Lal Ventures Private Limited (a wholly owned subsidiary) in their meeting held on 24 July 2026 had approved subscription of equity stake of 30% in Neuome Technologies Private Limited engaged in developing innovative solutions in sample preservation, pre-analytical technologies and bio banking business for a consideration of INR 35 million. The said subscription was completed on 27 August,2026 as per the terms and conditions of the Share subscription agreement. Pursuant to completion of the aforesaid subscription, Neuome Technologies Private Limited has now become associate of the Group and is accounted for using the equity method in accordance with IND AS 28 'Investment in Associates and Joint ventures'.

viii. On 24 September 2026, the Board of Directors of the Parent Company approved the acquisition of a 70% stake in SN Genelab Private Limited ("SN Gene") for a cash consideration of up to INR 1,680 million, plus a certain performance-linked earn-out capped at INR 315 million. The transaction was concluded on 1 October 2026, and SN Gene has become a subsidiary of the Company w.e.f 1 October, 2026. SN Gene is primarily engaged in business of providing Diagnostics- Genomics Services.

ix. Subsequent to 30 September 2026, the Parent Company invested an additional INR 303 million in Pathlabs Unifiers Private Limited (PUPL) through subscription to additional equity shares. The funds were utilized by PUPL to acquire the remaining 30% stake in Centrapath Labs Private Limited (CPL) for a consideration of INR 303 million, resulting in CPL becoming a wholly owned subsidiary of PUPL.

x. The shareholders of the Parent Company on 07 December, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of Rs.10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed 19 December, 2025 as record rate. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on 22 December, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the quarter and six months ended 30 September, 2025 have been restated to give effect to the allotment of the bonus shares.

xi. On 21 November, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Group has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by INR 301.00 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount as "Impact of Labour Codes" under "Exceptional Item" in the Consolidated Statement of Profit and Loss for the year ended 31 March, 2026.

xii. During the previous year, the Group has regrouped manpower cost aggregating to INR 86 million and INR 167 million respectively for the quarter and half year ended 30 September, 2025, representing collection and transportation charges carried out through third party from employee benefit expenses to other expenses in line with the nature of contract.

xiii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.

xiv. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities and Annexure-B for Consolidated Cash Flow Statement.

For and on behalf of the Board of Directors of
**Dr. Lal PathLabs Limited**

**(Hony) Brig. Dr. Arvind Lal**
Executive Chairman

Place: Gurugram
Date: 4 November, 2026

PS

Annexure A

**Dr. Lal PathLabs Limited**

**Statement of Consolidated Assets and Liabilities**

**(INR in millions except as stated)**

| Particulars | As at 30 September, 2026 | As at 31 March, 2026 |
|---|---|---|
| | (Unaudited) | (Audited) |
| **Assets** | | |
| **1 Non-current assets** | | |
| (a) Property, plant and equipment | 3,154 | 3,097 |
| (b) Right-of-use assets | 2,060 | 1,741 |
| (c) Capital work-in-progress | 49 | 55 |
| (d) Investment Property | 325 | 328 |
| (e) Goodwill | 5,857 | 5,482 |
| (f) Other intangible assets | 1,701 | 1,915 |
| (g) Intangible assets under development | 8 | 10 |
| (h) Financial assets | | |
| (i) Investment accounted for using equity method | 34 | - |
| (ii) Loans | - | 1 |
| (iii) Other financial assets | 1,556 | 2,093 |
| (i) Non-current tax assets (net) | 151 | 191 |
| (j) Deferred tax assets (net) | 836 | 875 |
| (k) Other non-current assets | 14 | 6 |
| **Total non-current assets** | **15,745** | **15,794** |
| **2. Current assets** | | |
| (a) Inventories | 564 | 439 |
| (b) Financial assets | | |
| (i) Investments | 5,269 | 4,226 |
| (ii) Trade receivables | 1,413 | 1,107 |
| (iii) Cash and cash equivalents | 3,435 | 2,428 |
| (iv) Bank balances other than (iii) above | 7,364 | 6,667 |
| (v) Loans | 22 | 18 |
| (vi) Other financial assets | 505 | 558 |
| (c) Other current assets | 259 | 223 |
| **Total current assets** | **18,831** | **15,666** |
| **Total assets** | **34,576** | **31,460** |
| **Equity and liabilities** | | |
| **1. Equity** | | |
| (a) Equity share capital | 1,678 | 1,676 |
| (b) Other equity | 25,767 | 23,406 |
| **Equity attributable to the owners of the Company** | **27,445** | **25,082** |
| Non-controlling interest | 350 | 331 |
| **Total equity** | **27,795** | **25,413** |
| **2. Liabilities** | | |
| **Non-current liabilities** | | |
| (a) Financial liabilities | | |
| (i) Lease liabilities | 1,724 | 1,454 |
| (ii) Other financial liabilities | 135 | |
| (b) Deferred tax liabilities (net) | 19 | 60 |
| (c) Provisions | 26 | 26 |
| **Total non-current liabilities** | **1,904** | **1,540** |
| **Current liabilities** | | |
| (a) Financial liabilities | | |
| (i) Lease liabilities | 609 | 536 |
| (ii) Trade payables | | |
| Total outstanding dues of micro enterprises and small enterprises; and | 165 | 171 |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 1,691 | 1,635 |
| **Sub-total** | **1,856** | **1,806** |
| (iii) Other financial liabilities | 856 | 936 |
| (b) Provisions | 833 | 738 |
| (c) Current tax liabilities (net) | 323 | 71 |
| (d) Other current liabilities | 400 | 420 |
| **Total current liabilities** | **4,877** | **4,507** |
| **Total liabilities** | **6,781** | **6,047** |
| **Total equity and liabilities** | **34,576** | **31,460** |

RS

Annexure B

**Dr. Lal PathLabs Limited**

**Consolidated Cash Flow Statement**

(INR in millions except as stated)

| Particulars | Year to date figures for the current period ended 30 September, 2026 | Year to date figures for the previous period ended 30 September, 2025 |
|---|---|---|
| | (Unaudited) | (Unaudited) |
| **Cash flows from operating activities** | | |
| Profit for the year | 3,644 | 2,862 |
| **Adjustments for :** | | |
| Tax expense | 1,248 | 985 |
| Interest income | (351) | (335) |
| Gain on sale or fair valuation of investments | (205) | (157) |
| Rental income from investment property | (17) | (17) |
| Profit on disposal/discard of property, plant and equipment (net) | 2 | (2) |
| Expense recognised in respect of employee share based compensation | 89 | 138 |
| Finance cost | 133 | 95 |
| Depreciation and amortisation expense | 913 | 751 |
| Provision for impairment of trade receivables and advances | 36 | 7 |
| Bad debts and advances written off | 3 | 13 |
| Exchange differences on translation of foreign operations | (5) | 1 |
| **Operating profit before working capital changes** | **5,490** | **4,341** |
| **Adjustment for (increase)/decrease in operating assets:** | | |
| (Increase)/decrease in inventories | (125) | (141) |
| (Increase)/decrease in trade receivables | (344) | (150) |
| (Increase)/decrease in loans | (3) | (7) |
| (Increase)/decrease in other financial assets | (16) | (26) |
| (Increase)/decrease in other assets | (46) | (39) |
| **Adjustment for increase/(decrease) in operating liabilities:** | | |
| Increase/(decrease) in trade payables | 50 | 119 |
| Increase/(decrease) in other financial liabilities | -106 | 28 |
| Increase/(decrease) in provisions | 102 | 67 |
| Increase/(decrease) in other liabilities | (18) | (121) |
| **Cash generated from operations** | **4,984** | **4,071** |
| Income taxes paid | (962) | (831) |
| **Net cash generated by operating activities (a)** | **4,022** | **3,240** |
| **Cash flows from investing activities** | | |
| Payments for purchase of property, plant and equipment | (399) | (1,344) |
| Proceeds from disposal of property, plant and equipment | 4 | 4 |
| Payments for purchase of other intangible assets | (148) | (48) |
| Rental income from investment property | 17 | 17 |
| Interest received | 413 | 472 |
| Net cash outflow for investment in subsidaries | (201) | - |
| Net cash outflow for investment in Associates | (35) | |
| Payments for purchase of investments in mutual funds | (5,302) | (2,924) |
| Proceeds from sale of investments in mutual funds | 4,463 | 1,493 |
| Bank deposits placed with the banks | (5,796) | (7,482) |
| Bank deposits with banks encashed | 5,644 | 5,932 |
| **Net cash used in investing activities (b)** | **(1,340)** | **(3,880)** |
| **Cash flows from financing activities** | | |
| Proceeds from exercise of share options | 162 | 177 |
| Interest paid | - | (1) |
| Repayment of lease liability | (193) | (180) |
| Interest paid on lease liability | (131) | (94) |
| Dividend paid on equity shares | (1,513) | (1,027) |
| **Net cash used in financing activities (c)** | **(1,675)** | **(1,125)** |
| **Net increase/(decrease) in cash and cash equivalents (a+b+c)** | 1,007 | (1,765) |
| Cash and cash equivalents at the beginning of the year | 2,428 | 2,926 |
| **Cash and cash equivalents at the end of the year** | **3,435** | **1,161** |
| **Components of cash and cash equivalents** | | |
| Cash on hand | 14 | 14 |
| Balance with scheduled banks: | | |
| - on current accounts | 1,832 | 190 |
| - deposits with maturity of less than 3 months | 1,589 | 957 |
| **Cash and cash equivalents in Cash Flow Statement** | **3,435** | **1,161** |

PS

# Deloitte
# Haskins & Sells LLP

**Chartered Accountants**
7th Floor Building 10
Tower B
DLF Cyber City Complex
DLF City Phase II
Gurugram-122 002
Haryana, India

Tel: +91 124 679 2000
Fax: +91 124 679 2012

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF**
**Dr. LAL PATHLABS LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Dr. Lal PathLabs Limited** ("the Company"), for the quarter and six months ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm Registration No.: 117366W/W-100018)

Deloitte Haskins & Sells LLP Chartered Accountants

**RASHIM TANDON**
Partner
Membership No: 95540)
(UDIN: 26095540CDIEMY3488)

Place: Gurugram
Date: November 4, 2026

**Dr. Lal PathLabs Limited**

**CIN: L74899DL1995PLC065388**

**Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085**

**Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana**

**Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com**

**Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 September, 2026**

**(INR in million except as stated)**

| | Particulars | 3 months ended 30 September, 2026 | Preceding 3 months ended 30 June, 2026 | Corresponding 3 months ended in previous 30 September, 2025 | Year to date figures for the current period ended 30 September, 2026 | Year to date figures for the previous period ended 30 September, 2025 | Previous year ended 31 March, 2026 |
|---|---|---|---|---|---|---|---|
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | **Income** | | | | | | |
| | (a) Revenue from operations | 8,321 | 7,644 | 6,996 | 15,965 | 13,403 | 26,476 |
| | (b) Other income | 339 | 299 | 228 | 638 | 491 | 1,127 |
| | **Total income** | **8,660** | **7,943** | **7,224** | **16,603** | **13,894** | **27,603** |
| 2 | **Expenses** | | | | | | |
| | (a) Cost of materials consumed | 1,536 | 1,443 | 1,347 | 2,979 | 2,573 | 5,080 |
| | (b) Employee benefits expense | 1,299 | 1,250 | 1,165 | 2,549 | 2,343 | 4,752 |
| | (c) Finance costs | 69 | 61 | 46 | 130 | 91 | 220 |
| | (d) Depreciation and amortisation expense | 432 | 400 | 385 | 832 | 713 | 1,541 |
| | (e) Fees to collection centers/channel partners | 1,266 | 1,140 | 1,065 | 2,406 | 2,004 | 3,948 |
| | (f) Other expenses | 1,649 | 1,426 | 1,268 | 3,075 | 2,498 | 5,159 |
| | **Total expenses** | **6,251** | **5,720** | **5,276** | **11,971** | **10,222** | **20,700** |
| 3 | **Profit before exceptional items and tax** | **2,409** | **2,223** | **1,948** | **4,632** | **3,672** | **6,903** |
| 4 | **Exceptional items**<br>Impact of Labour Codes (See note ix) | - | - | - | - | - | 301 |
| 5 | **Profit before tax** | **2,409** | **2,223** | **1,948** | **4,632** | **3,672** | **6,602** |
| 6 | Tax expense | | | | | | |
| | (a) Current tax | 627 | 573 | 449 | 1,200 | 858 | 1,506 |
| | (b) Deferred tax | (15) | (9) | 42 | (24) | 64 | 14 |
| | **Total tax expense** | **612** | **564** | **491** | **1,176** | **922** | **1,520** |
| 7 | **Profit for the period (A)** | **1,797** | **1,659** | **1,457** | **3,456** | **2,750** | **5,082** |
| 8 | **Other comprehensive income/(loss)** | | | | | | |
| | Items that will not be reclassified to profit or loss<br>-Remeasurement of the defined benefit obligations | (8) | 17 | 18 | 9 | 6 | 67 |
| | -Income tax in relation to the items that will not be reclassified to profit or loss | - | (4) | (5) | (4) | (2) | (17) |
| | **Total other comprehensive income/(loss) (B)** | **(8)** | **13** | **13** | **5** | **4** | **50** |
| 9 | **Total comprehensive income (A+B)** | **1,789** | **1,672** | **1,470** | **3,461** | **2,754** | **5,132** |
| 10 | Paid-up equity share capital (Face value of INR 10 per share) | 1,678 | 1,676 | 838 | 1,678 | 838 | 1,676 |
| 11 | Other equity | | | | | | 23,053 |
| 12 | Earnings per share (INR)<br>(Face value of INR 10 per share)<br>(not annualised for quarters) (See note viii) | | | | | | |
| | - Basic | 10.75 | 9.94 | 8.73 | 20.69 | 16.48 | 30.45 |
| | - Diluted | 10.73 | 9.92 | 8.72 | 20.64 | 16.45 | 30.40 |

DC

**Dr. Lal PathLabs Limited**

**Notes to the Standalone Financials Results**

**Notes:**

i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 4 November, 2026. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended 30 September, 2026 and they have expressed an unmodified conclusion on the aforesaid results.

ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

iii. During the quarter and six months ended 30 September 2026, the Company has issued 211,050 and 293,800 equity shares of face value of INR 10 each respectively , to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").

iv. The Board of Directors of the Company have approved second interim dividend of INR 5 per equity share (face value of INR 10 each) at their meeting held on 4 November, 2026

The Board of Directors of the Company had approved an interim dividend of INR 5 per equity share (face value of INR 10 each) at their meeting held on 24 July, 2026 and this was paid on 11 August, 2026

The Board of Directors of the Company had proposed final dividend of INR 4 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2026. The same was approved by the shareholders in the Annual General Meeting held on 25 July, 2026 and this was paid on 31 July, 2026

v. **Acquistions during the half year ended 30 September, 2026**

**a.** During the six months ended 30 September 2026, the Company has acquired 100% Stake in Shahbazkers Diagnostic Centre Private Limited ("SDCPL") on 1 May, 2026 as per the terms and conditions of the Share Purchase Agreement for a cash consideration of INR 200 million. Pursuant to completion of the aforesaid acquisition, Shahbazkers Diagnostic Centre Private Limited has now become a wholly-owned subsidiary of the Company. SDCPL is primarily engaged in providing diagnostics and healthcare services.

**b.** During the six months ended 30 September 2026, A wholly owned subsidiary, Dr Lal Pathlabs FZCO has been incorporated in Dubai, United Arab Emirates. The Company has subscribed to 19,135 equity shares for AED 1,000 each for a total consideration of AED 19 million.

**c.** During the six months ended 30 September 2026, the Company has made a further investment of INR 77.5 million in its wholly owned subsidiary, Dr. Lal Ventures Private Limited, through subscription of additional equity shares.

vi. Subsequent to 30 September 2026, the Parent Company invested an additional INR 303 million in Pathlabs Unifiers Private Limited (PUPL) through subscription to additional equity shares. The funds were utilized by PUPL to acquire the remaining 30% stake in its subsidiary Centrapath Labs Private Limited (CPL) for a consideration of INR 303 million, resulting in CPL becoming a wholly owned subsidiary of PUPL.

vii. On 24 September 2026, the Board of Directors of the Company approved the acquisition of a 70% stake in SN Genelab Private Limited ("SN Gene") for a cash consideration of up to INR 1,680 million, plus a certain performance-linked earn-out capped at INR 315 million. The transaction was concluded on 1 October 2026, and SN Gene has become a subsidiary of the Company w.e.f 1 October, 2026. SN Gene is primarily engaged in business of providing Diagnostics- Genomics Services.

viii. The shareholders of the Company on 7 December, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of INR 10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed 19 December, 2025 as record rate. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on 22 December, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the quarter and Period ended 30 September,2025 have been restated to give effect to the allotment of the bonus shares.

ix. On 21 November, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by 301 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount as "Impact of Labour Codes" under "Exceptional Item" in the Standalone Statement of Profit and Loss for the year ended 31 March, 2026.

x. During the previous year, the Company has regrouped manpower cost aggregating to INR 86 million and INR 166 million respectively for the quarter and half year ended 30 September, 2025, representing collection and transportation charges carried out through third party from employee benefit expenses to other expenses in line with the nature of contract.

xi. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.

xii. Refer Annexure A for Statement of Standalone Assets and Liabilities and Annexure B for Standalone Cash Flow Statement

For and on behalf of the Board of Directors of
**Dr. Lal PathLabs Limited**

**(Hony) Brig. Dr. Arvind Lal**
Executive Chairman

Place: Gurugram
Date: 4 November, 2026

Annexure A

**Dr. Lal PathLabs Limited**
**Statement of Standalone Assets and liabilities**
**(INR in millions except as stated)**

| Particulars | As at 30 September, 2026 (Unaudited) | As at 31 March, 2026 (Audited) |
|---|---|---|
| **Assets** | | |
| **1. Non-current assets** | | |
| (a) Property, plant and equipment | 2,978 | 2,997 |
| (b) Right-of-use assets | 2,012 | 1,697 |
| (c) Capital work-in-progress | 45 | 55 |
| (d) Investment property | 325 | 328 |
| (e) Goodwill | 4,711 | 4,711 |
| (f) Other intangible assets | 1,399 | 1,699 |
| (g) Intangible assets under development | 8 | 10 |
| (h) Financial assets | | |
| (i) Investments | 1,919 | 1,139 |
| (ii) Loans | - | 1 |
| (iii) Other financial assets | 1,482 | 1,929 |
| (i) Non-current tax assets (net) | 118 | 159 |
| (j) Deferred tax assets (net) | 834 | 815 |
| (k) Other non-current assets | 4 | 6 |
| **Total non-current assets** | **15,835** | **15,546** |
| **2. Current assets** | | |
| (a) Inventories | 519 | 406 |
| (b) Financial assets | | |
| (i) Investments | 4,900 | 3,993 |
| (ii) Trade receivables | 1,531 | 1,342 |
| (iii) Cash and cash equivalents | 2,791 | 2,344 |
| (iv) Bank balances other than (iii) above | 7,012 | 6,094 |
| (v) Loans | 21 | 17 |
| (vi) Other financial assets | 472 | 535 |
| (c) Other current assets | 247 | 215 |
| **Total current assets** | **17,493** | **14,946** |
| **Total assets** | **33,328** | **30,492** |
| **Equity and liabilities** | | |
| **1. Equity** | | |
| (a) Equity share capital | 1,678 | 1,676 |
| (b) Other equity | 25,258 | 23,053 |
| **Total equity** | **26,936** | **24,729** |
| **2. Liabilities** | | |
| **Non-current liabilities** | | |
| (a) Financial liabilities | | |
| (i) Lease liabilities | 1,699 | 1,419 |
| (ii) Other financial liabilities | 41 | - |
| **Total non-current liabilities** | **1,740** | **1,419** |
| **Current liabilities** | | |
| (a) Financial liabilities | | |
| (i) Lease liabilities | 570 | 510 |
| (ii) Trade payables | | |
| Total outstanding dues of micro enterprises and small enterprises | 160 | 168 |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 1,626 | 1,591 |
| **Subtotal** | **1,786** | **1,759** |
| (iii) Other financial liabilities | 800 | 896 |
| (b) Provisions | 805 | 718 |
| (c) Current tax liabilities (net) | 317 | 69 |
| (d) Other current liabilities | 374 | 392 |
| **Total current liabilities** | **4,652** | **4,344** |
| **Total liabilities** | **6,392** | **5,763** |
| **Total equity and liabilities** | **33,328** | **30,492** |

PS

Annexure B

**Dr. Lal PathLabs Limited**
**Standalone Cash Flow Statement**

(INR in millions except as stated)

| Particulars | Year to date figures for the current period ended 30 September, 2026 | Year to date figures for the previous period ended 30 September, 2025 |
|---|---|---|
| | (Unaudited) | (Unaudited) |
| **Cash flows from operating activities** | | |
| Profit for the period | 3,456 | 2,750 |
| **Adjustments for :** | | |
| Tax expense | 1,176 | 922 |
| Interest income | (321) | (309) |
| Rental income from investment property | (17) | (17) |
| Dividend income from a subsidiary company | (16) | - |
| Net gain on sale or fair valuation of investments (at FVTPL) | (194) | (145) |
| Net Gain on sale of investments (net) | (2) | |
| (Profit)/Loss on disposal / discard of property, plant and equipment (net) | 2 | (2) |
| Expense recognised in respect of employee share based compensation | 89 | 138 |
| Finance costs | 130 | 91 |
| Depreciation and amortisation expense | 832 | 713 |
| Provision for impairment of trade receivables and advances | 140 | 9 |
| Bad debts and advances written off | 3 | 13 |
| **Operating profit before working capital and other changes** | **5,278** | **4,183** |
| **Changes in working capital:** | | |
| **Adjustment for (increase)/decrease in operating assets:** | | |
| (Increase)/Decrease in inventories | (113) | (137) |
| (Increase)/Decrease in trade receivables | (331) | (179) |
| (Increase)/Decrease in loans | (3) | (7) |
| (Increase)/Decrease in other financial assets | (10) | (26) |
| (Increase)/Decrease in other assets | (32) | (38) |
| **Adjustment for increase/(decrease) in operating liabilities:** | | |
| Increase/(decrease) in trade payables | 28 | 106 |
| Increase/(decrease) in other financial liabilities | (112) | 26 |
| Increase/(decrease) in provisions | 96 | 56 |
| Increase/(decrease) in other liabilities | (20) | (109) |
| **Cash generated from operations** | **4,781** | **3,855** |
| Income taxes paid (net) | (911) | (779) |
| **Net cash generated from operating activities (a)** | **3,870** | **3,076** |
| **Cash flows from investing activities** | | |
| Payments for purchase of property, plant and equipment | (311) | (1,327) |
| Proceeds from disposal of property, plant and equipment | 3 | 4 |
| Payments for purchase of other intangible assets | (6) | (45) |
| Dividend received from a subsidiary company | 16 | - |
| Interest received | 392 | 452 |
| Rental income from investment property | 17 | 17 |
| Investment in subsidaries | (700) | - |
| Payments for purchase of investments in mutual funds | (5,150) | (2,664) |
| Proceeds from sale of investments in mutual funds | 4,438 | 1,322 |
| Bank deposits placed with the banks | (5,542) | (7,307) |
| Bank deposits with banks encashed | 5,073 | 5,776 |
| **Net cash used in investing activities (b)** | **(1,770)** | **(3,772)** |
| **Cash flows from financing activities** | | |
| Proceeds from exercise of share options | 162 | 177 |
| Repayment of lease liability | (185) | (176) |
| Interest paid on lease liability | (127) | (90) |
| Interest paid | - | (1) |
| Dividend paid on equity shares | (1,503) | (1,001) |
| **Net cash used in financing activities (c)** | **(1,653)** | **(1,091)** |
| **Net increase/ (decrease) in cash and cash equivalents (a+b+c)** | **447** | **(1,787)** |
| Cash and cash equivalents at the beginning of the year | 2,344 | 2,666 |
| **Cash and cash equivalents at the end of the period/year** | **2,791** | **879** |
| **Components of cash and cash equivalents** | | |
| Cash on hand | 12 | 13 |
| Balance with scheduled banks: | | |
| - on current accounts | 1,590 | 132 |
| - deposits with maturity of less than 3 months | 1,189 | 734 |
| **Total cash and cash equivalents in Cash Flow Statement** | **2,791** | **879** |

PS

**ANNEXURE - B**

**DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:**

| SN | Particulars | Ms. Vasuta Agarwal |
|---|---|---|
| 1 | Reasons for change viz appointment/ ~~reappointment, resignation, removal, death or otherwise~~ | Appointment of Ms. Vasuta Agarwal as an Additional Director designated as a Non-Executive Independent Director on the Board of the Company |
| 2 | Date of Appointment/ ~~Re-appointment~~ & term of appointment/ ~~re-appointment~~ | **Date of Appointment:**<br>November 04, 2026<br><br>**Term of Appointment:**<br>Appointment of Ms. Vasuta Agarwal as an Independent Director shall be effective from November 04, 2026 for a term of three (3) consecutive years, subject to the approval of Members of the Company |
| 3 | Brief Profile (in case of appointment) | Ms. Vasuta Agarwal is a business and technology leader with experience across artificial intelligence, digital advertising, strategy and business operations. She is Chief Revenue Officer at Gnani.ai, where she leads growth and market expansion for a company building enterprise AI solutions for India and global markets.<br><br>Before joining Gnani.ai, Ms. Vasuta has also worked with InMobi, McKinsey & Company and Intel. She holds a PGDM in Business Administration and Management from the Indian Institute of Management Bangalore and a bachelor's degree in engineering from Birla Institute of Technology and Science, Pilani.<br><br>Her recognition includes the Economic Times 40 Under Forty list, Campaign Asia's 40 Under 40, the Economic Times Women Ahead list and IMPACT's list of influential women in media, marketing and advertising.<br><br>Ms. Vasuta Agarwal is on the board of IndiaMART InterMESH Limited, Kaya Limited, Iglulabs Software Private Limited and Valetez Services Private Limited |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | None |

**ANNEXURE - C**

**DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:**

| SN | Particulars | Details |
|---|---|---|
| 1 | Name of the target entity, details in brief such as size, turnover etc. | Dr. Lal PathLabs FZCO, Dubai, United Arab Emirates ("LPL Dubai"), is a Wholly Owned Subsidiary of Dr. Lal PathLabs Limited ("LPL"). It was incorporated to make strategic investments in diagnostics and allied activities, including potential acquisitions, tie-ups or joint ventures. LPL Dubai has invested in Sunshine Healthcare Limited, Ghana ("SHL"), which became its subsidiary following the investment.<br><br>**Turnover of LPL Dubai:** Not Applicable, since it was incorporated on June 12, 2026.<br><br>**Turnover of SHL (In INR):**<br>FY 26: 244 Mn.<br>FY 25: 240 Mn.<br>FY 24: 217 Mn. |
| 2 | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | LPL Dubai is Wholly Owned Subsidiary of LPL, a related party of LPL.<br><br>The proposed transactions are in the nature of related party transaction and will be on an arm's length basis. |
| 3 | Industry to which the entity being acquired belongs | Healthcare Diagnostics |
| 4 | Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | The proposed investment is intended for meeting business and operational requirements of LPL Dubai, including making further investment in its Subsidiary, SHL. |
| 5 | Brief details of any governmental or regulatory approvals required for the acquisition | The Company will obtain required regulatory approvals, if required, from the authorities in the relevant jurisdictions. |
| 6 | Indicative time period for completion of the acquisition | The transaction is expected to be completed by March 31, 2027, or such other dates as mutually agreed between the parties. |
| 7 | Consideration - whether cash consideration or share swap or any other form and details of the same | Cash Consideration |
| 8 | Cost of acquisition and/or the price at which the shares are acquired | Investment of an amount upto INR 49.5 Crores in LPL Dubai. (Including further investment of an amount upto INR 30 Crores in SHL by LPL Dubai) |

| | | |
|---|---|---|
| 9 | Percentage of shareholding / control acquired and / or number of shares acquired | LPL Dubai shall continue to remain Wholly Owned Subsidiary of LPL. |
| 10 | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | LPL Dubai was incorporated on June 12, 2026, under the Company Regulations of the DMCC Authority, Dubai, UAE, to strategically invest in Diagnostics and allied activities. This includes exploring potential acquisitions, tie-ups, or joint ventures.<br><br>SHL was incorporated on September 07, 2010, under the laws of Ghana and is engaged in business of providing Healthcare/ Diagnostics services.<br><br>Turnover: As mentioned in Clause 1 above |